Related Experiment Video
Updated: Aug 8, 2026

Synthesis and Evaluation of a Ruthenium-based Mitochondrial Calcium Uptake Inhibitor
Published on: October 26, 2017
The antitussive activity of a novel compound RU 20201
A novel compound, RU 20201, demonstrates potent antitussive effects comparable to codeine in animal studies. Its local activity in the lungs suggests a direct mechanism on respiratory tract receptors.
Area of Science:
- Pharmacology
- Respiratory Medicine
- Drug Discovery
Background:
- Codeine is a widely used antitussive agent.
- Novel compounds are sought to improve cough suppression with potentially fewer side effects.
- Understanding the mechanism of action of new antitussive agents is crucial.
Purpose of the Study:
- To evaluate the antitussive activity of a novel compound, 1,2,3,4,4a,9b-hexahydro-8,9b-dimethyl-4-[3-(4-methylpiperazin-1-yl)propionamido]dibenzofuran-3-one dihydrochloride (RU 20201).
- To compare its efficacy with codeine phosphate.
- To investigate the potential mechanism of action and delivery routes.
Main Methods:
- Oral administration of RU 20201 and codeine phosphate in animal models.
- Aerosol administration of RU 20201 to assess local antitussive activity.
- Observation of immediate effects post-administration.
Main Results:
- RU 20201 exhibited comparable antitussive activity to codeine phosphate after oral administration.
- Aerosolized RU 20201 demonstrated immediate local antitussive effects.
- The compound appears to act directly on superficial receptors in the respiratory tract.
Conclusions:
- RU 20201 is a promising antitussive compound with efficacy similar to codeine.
- Its ability to act locally via aerosol suggests a targeted approach for cough suppression.
- Further research into the direct inhibition of respiratory tract receptors is warranted.
More Related Videos
06:03Use of Viral Entry Assays and Molecular Docking Analysis for the Identification of Antiviral Candidates against Coxsackievirus A16
Published on: July 15, 2019
10:29Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Related Concept Videos
Drugs Used in Upper Respiratory Disorders: Overview
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
Upper Respiratory Drugs: Decongestants
Most decongestants are readily available over-the-counter in various...
Upper Respiratory Drugs: First and Second-Generation Antihistamines
Histamine binds to specific receptor sites, known as H1 receptors, on tissue cells, triggering inflammation and swelling. Antihistamines combat these effects by competing with histamine for these receptor sites. By...
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by anesthetizing...
Antiasthma Drugs: Methylxanthines
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Antiasthma Drugs: Muscarinic Receptor Antagonists
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...